Gordon Cook
Leeds Institute of Clinical Trials Research · University of Leeds · St. James's University Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gordon Cook as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:13 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07649525 · Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelUniversity of Leeds · recruiting · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) · study chair
- Ph3NCT03720041 · Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaUniversity of Leeds · unknown · Multiple Myeloma · principal investigator
- Ph1NCT03015922 · Viral Immunotherapy in Relapsed/Refractory Multiple MyelomaUniversity of Leeds · unknown · Multiple Myeloma · principal investigator
- Ph2NCT02461888 · Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.University of Leeds · completed · Multiple Myeloma · principal investigator
- Ph3NCT00747877 · High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After ChemotherapyLeeds Cancer Centre at St. James's University Hospital · unknown · Multiple Myeloma and Plasma Cell Neoplasm · principal investigator
- Ph3NCT00006232 · Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple MyelomaWest of Scotland Lymphoma Group · completed · Multiple Myeloma and Plasma Cell Neoplasm · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 10:13 UTC. The ranking covers the 200 most relevant of 68 PubMed records, and a shared surname and initials can bring in a namesake. All 68 on PubMed
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.J Clin Oncol · 2015472 citationsRCR 12.9
- 440 citationsRCR 11.1
- Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.J Clin Oncol · 2013339 citationsRCR 9.4
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2019309 citationsRCR 11.7
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.Blood · 2012273 citationsRCR 7.9
- 197 citationsRCR 9.0
- A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.Br J Haematol · 2013185 citationsRCR 6.4
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.Haematologica · 2018181 citationsRCR 6.5
- 155 citationsRCR 3.9
- 147 citationsRCR 4.9